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Hepatocellular carcinoma (HCC) is one of the most frequent
human cancers throughout the world. Epidemiological studies
have indicated that infection with the hepatitis B virus (HBV) or
hepatitis C virus (HCV) and ingestion of foods contaminated by
aflatoxins predisposes to HCC (Bressac et al, 1991; Hsu et al,
1991). Recent advances in molecular genetics have revealed that
the genesis of human cancer is attributed to multiple genetic alter-
ations, including both proto-oncogenes and tumour-suppressor
genes (Vogelstein et al, 1988). This is also the case in hepato-
cellular carcinogenesis as suggested in animal experiments
(Woodchuck HCC), which have demonstrated overexpression of a
rearranged c-myc proto-oncogene in HCCs (Möröy et al, 1986).
However, the molecular mechanisms of hepatocarcinogenesis are
still largely unclear.
The p53 tumour-suppressor gene has been shown to be mutated in
HCCs at variable frequencies (0–67%) (Buetow et al, 1989; Kress et
al, 1992; Coursaget et al, 1993; Nishida et al, 1993; Teramoto et al,
1994; Vesey et al, 1994; Kazachkov et al, 1996; Honda et al, 1998).
The relationship between p53 and HBV or HCV has also been found
to play a central role in the regulation of carcinogenesis and prolifer-
ation of HCC (Henkler et al, 1995; Wang et al, 1995; Lunn et al,
1997; Ray et al, 1997). In addition, many studies which demonstrate
loss of heterozygosity (LOH) of HCCs have recently been reported.
These include chromosomal loci 1p, 1q, 4q, 5q, 8p, 9p, 9q, 11p, 13q,
14q, 16q, 17p and 17q (Tsuda et al, 1990; Ding et al, 1991; Fujimori
et al, 1991; Nagai et al, 1997; Piao et al, 1997). The 1p LOH in
HCCs have been reported as 33% at D1S243, D1S214 and D1S228
(Kuroki et al, 1995), 48% at D1S160 (Yeh et al, 1994) and 80% at
D1S47 (Simon et al, 1991). Yeh et al (1994) have shown that the
genetic alteration in HCC appears to cluster at the region mapped to
1p35–36, suggesting the presence of tumour-suppressor gene(s) of
HCC in this particular region.
A novel gene, p73, encoding a protein homologous to p53 has
recently been identified (Kaghad et al, 1997). The p73 gene has a
remarkable sequence similarity to p53 in the domains of transcrip-
tional activation, DNA-binding and oligomerization (Kaghad et al,
1997). p73 activates the transcription of p53-responsive genes
such as p21waf1/cip1, inhibits cell growth and induces apoptosis (Jost
et al, 1997). Kaghad et al (1997) found monoallelic expression of
the p73 gene in neuroblastoma cell lines, suggesting that the gene
is imprinted. In addition, the fact that p73 has been mapped to
chromosome 1p36.33 led us to investigate genetic alterations of
p73 in primary HCCs.
MATERIALS AND METHODS
Specimens
Primary hepatocellular carcinomas and their corresponding non-
cancerous liver tissues were obtained from 48 patients who received
surgical resection at the Shinshu University Hospital, Nagano, Japan.
Aetiologically, 38 patients had HCV infection, six HBV infection,
two alcoholic liver cirrhosis, one cirrhosis due to Budd–Chiari
syndrome, and one normal liver. The tumours were untreated except
that Lipiodol Ultra-Fluide (Laboratoire Guerbet, Villepinte, France)
was transarterially injected for a diagnostic purpose. The tissues were
frozen immediately after surgery and stored at –80°C until used.
DNA was prepared with a QIAamp Tissue Kit (Qiagen, Hilden,
Germany). Total RNA was isolated from 43 out of the 48 cancerous
tissues and their corresponding non-cancerous tissues by the standard
protocol (Chomczynski et al, 1987).
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Reverse transcriptase (RT)-PCR analysis
First-strand cDNA synthesis was performed using 2 mg of total
RNA and Superscript II reverse transcriptase (Life Technologies,
Rockville, MD, USA). The mRNA expression of p73a and p73b
was measured by RT-PCR as described previously (Nimura et al,
1998). The primer sequences used for amplification of the poly-
morphic regions of the p73 gene are shown elsewhere (Nimura
et al, 1998).
Loss of heterozygosity analysis
To study LOH of the p73 gene, PCR reaction was performed with a
primer pair flanking a CT-repeat which we found in intron 9 of the
p73 gene (Nimura et al, 1998). The primer sequences used for p73
LOH were as follows: p73-LOH-F, 5¢-CCT CTT CCT CCC CTA
CCA AC-3¢; and p73-LOH-R, 5¢-TAG GCG ACA GAG CAA GAC
G-3¢. The amplification products of about 110 bp were electro-
phoresed on 6% denaturing polyacrylamide gels at 1500 V for 3 h.
PCR–single-strand conformation polymorphism (SSCP)
analysis
Amplification of the p73 genomic DNA was performed using
specific primer sets for each exon, which we previously designed
based on the nucleotide sequence information obtained from the
p73 P1 clone (Nimura et al, 1998). To search for mutations of p73
by PCR-SSCP analysis, exons 2–14, which cover the entire coding
region of human p73, were amplified. Electrophoresis was carried
out at room temperature at 200 V for 15 h. The gel was dried on a
sheet of filter paper using a gel dryer and exposed to radiographic
film at –80°C. PCR-SSCP analysis of the p53 gene was performed
according to the method described previously (Murakami et al,
1991). Three primer sets which cover the hotspot region in exons
5–9 of the p53 gene were used.
The PCR products which showed an aberrant migration pattern
on the SSCP gels were run on agarose gels and excised from the
gel. The DNA fragments were purified using GenElute Agarose
Spin Column (Supelco, Bellefonte, PA, USA) and subcloned into
the plasmid vector (pGem-T Easy Vector, Promega, Madison, WI,
USA). The individual clones were sequenced by the dideoxy-
nucleotide termination reaction method using the ABI Prism 377
DNA sequencer (Perkin-Elmer, Foster City, CA, USA).
RESULTS
Expression of p73 mRNA in HCCs
The  p73 transcripts were ubiquitously expressed in all 43
cancerous tissues and their corresponding non-cancerous liver
tissues by RT-PCR as shown in Figure 1, although the transcripts
were not detectable by Northern blot analysis (data not shown). In
all the samples, p73a was expressed at higher levels than p73b.
The semiquantitative PCR, which was done by changing the PCR
cycles, showed that the levels of p73 expression were similar in
cancerous and non-cancerous tissues of the liver (data not shown).
There was no significant correlation between p73 expression and
the aetiology of HCCs.
Loss of heterozygosity of the p73 gene in HCCs
Allelotyping of the p73 gene was performed using DNA from the
HCC tissues and the paired normal liver tissues. In 25 out of 48
(52%) HCCs, the LOH data were informative. LOH was found in
five (20%) tumours (Figure 2).
Mutation analysis of the p73 gene in HCCs
DNA from the 48 tumours was subjected to PCR-SSCP and DNA
sequencing. The DNA fragments which showed a mobility shift on
the SSCP gels were sequenced, and this revealed that there were
no mutations with amino acid substitution or frame shifts in the
coding region of the p73 gene. Polymorphisms at codons
Ala336Ala (GCC®GCT) plus His349His (CAT®CAC), Ala
557Ala (GCG®GCA) and Ala610Ala (GCG®GCA) were found
in seven (15%), four (9%) and seven (15%) respectively (Figure
3). Next, we examined the p53 mutations using PCR-SSCP of
exons 5–9, which corresponded to the DNA-binding domain.
Abnormally migrating bands were observed in 4 out of the 48 case
(8%) tumours.
DISCUSSION
p73 is a novel gene recently identified as a first family member of
the p53 tumour-suppressor gene. Like p53, a p73 protein is able to
activate the transcription of p53-responsive genes, such as
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Figure 1 Expression of p73a and p73b in hepatocellular carcinoma by RT-
PCR. The PCR products, 217 bp and 113 bp, correspond in size to p73a and
p73b without exon 13 respectively. Both transcripts were expressed in HCCs
(lanes 1–6) and the corresponding normal liver tissues (lanes 7–12) in a
similar pattern. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
amplified as a control
Figure 2 p73 loss of heterozygosity in hepatocellular carcinomas.
Autoradiograghs show representatives of LOH in HCCs. DNA was isolated
from the tumour (T) and the corresponding liver tissue (L). The patient’s
number is shown at the top of the autography. C17 had a loss of
heterozygosity (LOH+), C33 showed retention of both alleles (LOH–) and the
LOH of C42 was not informative (NI)
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p21waf1/cip1, to inhibit cell growth and to induce apoptosis (Kaghad
et al, 1997; Jost et al, 1997). Because of the close similarity
between p73 and p53 in both structure and function, it was
suggested that p73 might also be a tumour-suppressor gene. The
hypothesis was further supported by its chromosomal localization
at 1p36.3, which is a region frequently deleted in many cancers
including neuroblastoma and colon cancer. In addition, Kaghad et
al (1997) showed that expression of p73 was much lower in
neuroblastoma cell lines than in colorectal and breast cancer cell
lines, and suggested that the p73 gene was imprinted in neuro-
blastoma cell lines and normal blood leucocytes.
Our present results using RT-PCR, however, have shown that
p73 mRNA is ubiquitously expressed in HCCs. The levels of p73
expression appear to be similar in the HCC tissues and normal
liver tissues. p73 LOH was found in 20% of HCCs. However,
there were no mutations with amino acid substitution or
frameshifts in the tumours. These suggest that, in HCCs, the
putative p73 tumour-suppressor gene may function in a different
manner from the classical Knudson’s two-hit hypothesis
(Knudson, 1971). As previously suggested by Kaghad et al (1997),
one of the possibilities is the imprinting of the p73 gene. We are
currently examining whether or not p73 is imprinted in HCCs.
Another possibility is the interaction of p73 with, or regulation of
p73 by, the protein(s) of hepatitis viruses.
The role of p53 has been emphasized to be important in hepato-
cellular carcinogenesis. However, the frequency of p53 mutations
in HCC reported is variable (0–67%). Our present study showed
only 8% aberrant bands on PCR-SSCP, although examination was
limited to a hotspot region of exon 5–9. Wild type p53 is regulated
by the proteins of hepatitis viruses which contribute to malignant
transformation of hepatocytes. The HBV encodes a protein which
can physically bind to p53 and apparently blocks its normal func-
tion by arresting the cell cycle (Levine et al, 1991). HBx, an onco-
protein encoded by the X gene on HBV DNA, can form a complex
with p53 and inhibit its DNA-binding and transactivation function
(Nishida et al, 1993; Henkler et al, 1995; Wang et al, 1995). A
recent report has also shown that the core protein of HCV induces
down-regulation of p53 expression (Ray et al, 1997). Therefore,
like p53, the p73 function could also be regulated by the protein
product(s) of hepatitis viruses, although the mechanism remains to
be determined.
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